MetaCap

Lantheus (LNTH) vs Intellia Therapeutics (NTLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantheus (LNTH) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 82.9% versus a gain of 21.8%. Over five years, LNTH leads with a +266.1% price change compared with -91.2% for NTLA. Lantheus is the larger company by market cap ($6.68 billion vs $1.40 billion), about 4.8 times the size, while Intellia Therapeutics is growing revenue faster (+16.9% vs +0.5%).

Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -609.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+82.91%NTLA+21.80%
+123%+58%-7%
Nov 21, 20251 yearNov 20, 2026
LNTH+255.87%NTLA-92.28%
+351%+118%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus NTLA key metrics
MetricLNTHNTLA
Share price$102.10$10.00
Market cap$6.68B$1.40B
1-day change0.00%+5.04%
YTD return+53.42%+11.23%
1-year return+82.91%+21.80%
5-year return+266.08%-91.16%
P/E ratio (TTM)25.40—
Forward P/E15.34—
EPS (TTM)$4.02$-3.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B$67.67M
Revenue growth (YoY)+0.50%+16.92%
Net income (latest FY)$233.56M$-412.69M
Gross margin61.10%—
Operating margin20.16%-651.67%
Net margin15.15%-609.85%
52-week high$111.86$18.48
52-week low$54.94$8.09
Distance from 52-week high-8.73%-45.89%
Analyst consensusholdbuy
Avg. price target upside+3.81%+127.80%
Average volume1.02M5.03M
Shares outstanding65.40M140.36M
Employees1,193377
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lantheus is about 4.8 times larger than Intellia Therapeutics by market value ($6.68B vs $1.40B).
  • LNTH has outperformed NTLA by 61.1 percentage points over the past year.
  • Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
  • Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs +0.50%).

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About Intellia Therapeutics

NTLA stock →

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees

LNTH vs NTLA FAQ

Which is bigger, Lantheus or Intellia Therapeutics?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $1.40B for Intellia Therapeutics (NTLA).

Which stock has performed better over the past year, LNTH or NTLA?

LNTH returned +82.91% over the past 12 months, compared with +21.80% for NTLA (price return, excluding dividends). Past performance does not predict future results.

Are Lantheus and Intellia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons